This report covers the 68 geographical markets and provides an Excel-based forecast model for the Multiple Sclerosis market through 2034.
The analyst estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 67.0% and 62.9% of 68-market sales in 2024 and 2034, respectively.
The analyst estimated that the MS market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%. Across the 68 markets, sales in the Multiple Sclerosis market were $32.8 billion in 2024, growing to $41.2 billion in 2034.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 67.0% and 62.9% of 68-market sales in 2024 and 2034, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast (PBF) sales for Multiple Sclerosis, covered in the analyst’s report “Multiple Sclerosis: Seven - Market Drug Forecast and Market Analysis”, published in June 2025. In addition to PBF sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the MS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the MS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Executive Summary1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology
2.2.2 68M forecast extrapolation methodology
2.3 Primary research - key opinion leaders interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Managing analyst
2.5.3 Therapy area directors
2.5.4 Epidemiologist
2.5.5 Epidemiology reviewers
2.5.6 Vice President of Disease Intelligence and Epidemiology
2.5.7 Global Head of Pharma Research, Analysis and Competitive Intelligence
3 About the Analyst
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bayer AG
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Co
- Novartis AG
- Merck KGaA
- Biogen Inc
- Mitsubishi Tanabe Pharma Corp
- MediciNova Inc
- Pfizer Inc
- Banner Life Sciences LLC
- AB Science SA
- Immunic Inc
- Sanofi
- MediciNova (Europe) Ltd
- TG Therapeutics Inc
- Clene Nanomedicine Inc
- InnoCare Pharma Ltd
- Handa Pharmaceuticals Inc
